Salmon DNA: The Molecular Identity Crisis

Salmon Sperm Is the Hottest Ingredient in Skincare. I Wish I Were Joking.

If you've been anywhere near skincare TikTok in the last year, you've encountered PDRN — polydeoxyribonucleotide — though you probably know it by its more Instagram-friendly name: "salmon DNA." The ingredient has become the centerpiece of Korean beauty's latest global export, promising everything from "glass skin" to collagen regeneration to cellular repair. Google searches for PDRN surged 153% year-over-year in 2025.¹ The cosmetic PDRN market is projected to balloon from $26 million to $285 million by 2030.²

The marketing pitch is irresistible: a clinically proven ingredient used by Korean dermatologists, now available in a serum you can apply at home. The clinical proof exists — I'll give them that. But here's the part the marketing conveniently omits: virtually all of that clinical evidence comes from injectable PDRN, not the topical serums sitting on Sephora shelves. These are fundamentally different delivery methods, and conflating them is like citing the efficacy of IV antibiotics to sell an antibiotic-scented candle.

I wanted to love this one. The science behind injectable PDRN is genuinely elegant. But wanting an ingredient to work topically and having proof that it does are different things — and right now, the proof doesn't exist.

What PDRN Actually Is (And Why the Name Matters)

PDRN stands for polydeoxyribonucleotide — a biologically active mixture of DNA fragments extracted from the sperm cells of salmon or trout. The extraction process involves high-temperature purification that strips away proteins and other cellular material, leaving behind oligonucleotide chains with molecular weights ranging from 50 to 1,500 kilodaltons (kDa) and a purity exceeding 95%.³

The primary mechanism of action is well-characterized: PDRN activates the adenosine A2A receptor on the surface of fibroblasts and endothelial cells.⁴ This triggers a signaling cascade — cAMP, PKA, CREB — that upregulates vascular endothelial growth factor (VEGF) for new blood vessel formation, stimulates collagen types I and III synthesis, and inhibits matrix metalloproteinase-1 (MMP-1), the protease responsible for collagen degradation.⁵ It also reduces inflammatory mediators through NF-κB pathway inhibition.

There's a secondary mechanism too: the salvage pathway. PDRN provides nucleotide building blocks that cells can recycle for their own DNA and RNA synthesis, essentially topping off the fuel tank without requiring de novo nucleotide production.⁴

On paper, this is beautiful pharmacology. The problem isn't the mechanism — it's whether these fragments can actually reach the cells that need them when you smear them on your face instead of injecting them under your skin.

Injectable PDRN: The Evidence That Started It All

Here's where I give PDRN its due. As an injectable pharmaceutical, it has a legitimate clinical track record — particularly for wound healing. This is the evidence the marketing materials reference, and it's real. Just not relevant to your serum.

The pattern is clear: injectable PDRN accelerates wound healing. Multiple RCTs, consistent results, clear mechanism of action. If you're a diabetic patient with chronic foot ulcers, PDRN injections are a legitimate and evidence-backed treatment option.

But notice what every one of these studies has in common: the PDRN was injected directly into or near the target tissue. Not applied topically. Not absorbed through intact skin. Injected. This distinction is the entire ballgame.

Topical PDRN: Where the Evidence Vanishes

Now let's talk about what you're actually buying when you purchase a PDRN serum. The most comprehensive assessment of PDRN in aesthetics comes from a 2025 systematic review by Lampridou and colleagues, published in the Journal of Cosmetic Dermatology.⁹ They searched Embase, Medline, and Cochrane for studies on polynucleotides in esthetic medicine from 2010 to 2024.

What they found is telling: nine studies, total population of 219 patients. The studies were rated as low-to-moderate quality. The evidence showed "promising outcomes" for reducing wrinkles and improving skin texture — but the authors couldn't even perform a meta-analysis because the studies were too heterogeneous to combine. Nine studies. 219 patients. To support a market projected to hit $285 million.

And here's the critical detail that gets lost in marketing: most of the aesthetic studies used injectable polynucleotides or combination therapies — not topical serums applied to intact skin. The one study that comes closest to testing topical PDRN for wrinkles used it in combination with microneedling.

Let me be blunt: I could not find a single published randomized controlled trial testing a topical PDRN serum — without microneedling, without injection, without any barrier disruption — on intact human skin for anti-aging. The clinical evidence that brands cite to sell you a $120 serum comes from needles, not bottles.

The 500-Dalton Rule and Why Your Serum Probably Doesn't Work

There's a well-established principle in dermatology called the 500-Dalton rule: molecules larger than 500 Daltons generally cannot penetrate the stratum corneum — the outermost layer of skin that functions as a barrier.¹¹ It's not a perfect rule, but it's a reliable guideline for predicting whether a topical ingredient will reach the living cells in your dermis.

PDRN molecules range from 50,000 to 1,500,000 Daltons. Even the smallest PDRN fragments are 100 times too large to cross intact skin. The average molecular weight in commercial serums is around 130,000 to 250,000 Daltons — roughly 260 to 500 times above the penetration threshold.³

To make matters worse, PDRN is highly hydrophilic — it loves water. The stratum corneum is a lipophilic barrier — it favors oil-soluble molecules. So PDRN is both too large and too water-loving to cross the skin barrier. It's like trying to push a refrigerator through a cat door while the cat door is coated in oil.

Researchers are working on solutions. Nano-encapsulation using phospholipid bilayer vesicles can theoretically increase bioavailability by 300–500% in cell culture experiments.¹² Plasma-engineered PDRN processing has shown a 2.29-fold improvement in cumulative permeation — but only in vitro, meaning in a lab, not on human skin.¹² Combining topical PDRN with microneedling creates micro-channels that bypass the barrier entirely — but at that point, you're paying for the microneedling, not the serum.

The most honest assessment comes from the researchers themselves. A 2025 review in the Journal of Skin Stem Cell acknowledged that topical PDRN shows promise with nano-encapsulation technology but conceded that there is limited human data validating whether these delivery innovations actually translate to clinical outcomes on human skin.¹³

A $285 Million Industry Built on 219 Patients

The PDRN market tells us more about the power of K-beauty marketing than about the ingredient's topical efficacy. South Korea dominates over 50% of global PDRN production.² The country's dermatology clinics have offered injectable PDRN treatments (branded as "Rejuran" or "salmon injections") since the early 2010s, at $500 to $1,500 per session in Seoul — and $1,000 to $2,000+ in the US, where practitioners use it off-label.¹⁴

The topical market is a more recent phenomenon, driven by the same logic that brought snail mucin and centella asiatica to Western consumers: if Korean dermatologists use it, it must work. Brands like Rejuran, VT Cosmetics, and CNP Laboratory now offer topical PDRN serums ranging from $40 to $200+ per bottle.¹⁴ Some brands have pivoted to "vegan PDRN" derived from plant sources like Korean ginseng — a move that raises its own questions about whether plant-derived polynucleotides activate the same A2A receptor pathway as salmon-derived PDRN.

A 2024 survey of Korean dermatologists published in the Journal of Cosmetic Dermatology found high utilization of injectable polynucleotides in clinical practice, with practitioners reporting perceived efficacy. But the survey also revealed standardization gaps — different concentrations, different injection techniques, different treatment intervals — making it difficult to establish a consistent protocol even for the injectable form.¹⁵

The broader PDRN market (including medical applications) is projected to grow from $321 million in 2025 to $811 million by 2035 — a 9.7% compound annual growth rate.² The cosmetic segment is the fastest-growing part of that market, driven almost entirely by consumer demand on social media rather than new clinical evidence.

Two Ingredients Wearing the Same Name

This is fundamentally a story about two different products sharing one name. Injectable PDRN and topical PDRN serums are not the same thing, don't deliver the ingredient the same way, and shouldn't be evaluated by the same evidence.